Reaction Biology Corporation (RBC) and PharmaCore Labs (PCL) announced a joint collaboration agreement in China. Under the terms of the agreement, PCL will supply business support and development personnel to RBC, as well as a staging facility for compound transshipment to the US. RBC will make its full suite of biochemical, cell, and in vivo assay services available to PCL for distribution in China. The arrangement is designed to make it more convenient for Chinese firms to use RBC's services, and also allows RBC to invoice in yuan.
"While we have dozens of customers in China currently, the market is much bigger than we could address remotely. We've found that PCL has a deep knowledge of the China drug discovery market, and we're happy to have their local expertise available to serve hundreds of potential customers in China. We offer services that are not otherwise available in China, including the largest panel of profiling and screening assays for over 730 kinases and 300 plus epigenetic targets, cell-based target engagement assays, and hollow fiber in vivo assays," Dr. Haiching Ma, Chief Science Officer of RBC, said.
"RBC has a unique portfolio of services. Since more and more Chinese companies are gearing up to do early stage drug discovery, we believe the Chinese market will generate significant demand. PCL is one of the well-known CRO's in China focusing on ion channel drug discovery and cardiac safety, with a client base covering over 50 % of Chinese pharmaceutical research labs. Our list of contacts in this industry will want to hear more from RBC,” Dr. Howard Zhang, President of PCL, said.